Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤ ÀÌÇ༼Æ÷¾Ï¿¡¼­ Membranous E-cadherinÀÇ ÀÓ»óÀû À¯¿ë¼º The Clinical Usefulness of Membranous E-cadherin in Transitional Cell Carcinoma of the Bladder

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 6È£ p.1219 ~ 1226
¼Ò¼Ó »ó¼¼Á¤º¸
¿ÀºÀ·Ä/Bong Ryoul Oh ³ª±æÁÖ/±è¼ºÁø/½ÉÀçÈ«/±Çµ¿µæ/¹Ú±¤¼º/·ù¼ö¹æ/¹Ú¾çÀÏ/Gil Joo Nah/Seong Jin Kim/Jae Hong Sim/Dong Deuk Kwon/Kwang Sung Park/Soo Bang Ryu/Yang Il Park

Abstract

¼­·Ð
¹æ±¤ ÀÌÇ༼Æ÷¾ÏÀº Çѱ¹¿¡¼­ °¡Àå ÈçÇÑ ºñ´¢±â°è ¾ÏÀ¸·Î Àüü ¾ÏÀÇ ¾à 3%¸¦ Â÷ÁöÇÏ¸ç ¹ß
»ýºóµµ°¡ Áõ°¡ Ãß¼¼¿¡ ÀÖ´Ù. ¹æ±¤¾ÏÀÇ ¿¹Èĸ¦ ¿¹ÃøÇÏ´Â ÀÎÀڷμ­ Á¶Á÷ÇÐÀû ºÐÈ­µµ¿Í ÀÓ»óÀû
º´±â°¡ »ç¿ëµÇ¾î ¿ÔÀ¸³ª ¹æ±¤¾ÏÀÇ ´Ù¾çÇÑ »ý¹°ÇÐÀû Ư¼ºÀ¸·Î ÀÎÇØ Á¤È®ÇÑ ¿¹Èĸ¦ ¿¹ÃøÇϱâ
°¡ Èûµç ½ÇÁ¤ÀÌ´Ù. ÀÌ ¶§¹®¿¡ °¢Á¾ Á¾¾çÇ¥ÁöÀÚ³ª ´Ù¸¥ ¿¹ÈÄÀÎÀÚ¸¦ ÀÌ¿ëÇÏ¿© ¾ÏÀÇ ÁøÇàÀ» ¿¹
ÃøÇÏ°í À̸¦ Åä´ë·ÎÇÑ È¯ÀÚ °³°³Àο¡ ´ëÇÑ Á¤È®ÇÏ°í ÀûÀýÇÑ Ä¡·á¹æ¹ýÀÇ °áÁ¤À» À§ÇÑ ¸¹Àº
½Ãµµ°¡ ÀÌ·ç¾îÁö°í ÀÖ´Ù.
ÃÖ±Ù ¾Ï¼¼Æ÷ÀÇ Ä§À±°ú ÀüÀÌ¿¡ ¼¼Æ÷ºÎÂøÀÎÀÚ(adhesion molecule)°¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °Í
À¸·Î ¾Ë·ÁÁö¸é¼­ ¾ÏÀÇ ÁøÇà°úÁ¤ ¿¹Ãø¿¡ ÀÖ¾î À̵鿡 ´ëÇÑ °ü½ÉÀÌ °íÁ¶µÇ°í ÀÖ´Ù. ¼¼Æ÷ÀÇ À¯
Áö±â´É ¹× ºÐÈ­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¼¼Æ÷ »óÈ£ÀÛ¿ë¿¡ ÀÖ¾î Áß¿ä ±â´ÉÀ» ÇÏ´Â ¼¼Æ÷ºÎÂøÀÎ
ÀÚÀÇ Áö±Ý±îÁö ¾Ë·ÁÁø Á¾·ù·Î´Â Immunoglobulin family, Integrin, Selectin, CadherinµîÀÌ
ÀÖ´Ù. Á¤»ó »óÇǸ¦ À¯ÁöÇϴµ¥ Áß¿äÇÑ ¹°ÁúÀÎ CadherinÀº ¼¼Æ÷¸· »çÀÌÀÇ 120 kDaÅ©±âÀÇ Ä®
½·ÀÇÁ¸¼º ´ç´Ü¹éÀ¸·Î »óÇǼ¼Æ÷ÀÇ ¼±ÅÃÀû ºÎÂø¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϸç E(epithelial),
N(neuronal), p(placental) cadherin µîÀÇ Á¾·ù°¡ ¾Ë·ÁÁ® ÀÖ´Ù.
¹æ±¤ ÀÌÇ༼Æ÷¾ÏÀ» Æ÷ÇÔÇÑ °¢Á¾ »óÇÇ¿¡¼­ ¹ß»ýÇÏ´Â ¾Ï°ú ¿¬°üµÈ E-cadherinÀº ¾Ï¼¼Æ÷ÀÇ
ħÀ± ¾ïÁ¦ÀÎÀڷμ­ÀÇ ±â´ÉÀÌ ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù. E-cadherinÀº ¼¼Æ÷¸·¿¡¼­ ¹ßÇöµÇ
´Â membranous form°ú À̵éÀÌ °¡¼öºÐÇصǾî Ç÷û ¹× ¿ä¿¡¼­ °ËÃâµÇ´Â soluble formÀÇ µÎ
°¡Áö ÇüÅ·ΠÁ¸ÀçÇÑ´Ù. Á¶Á÷³» membranous E-cadherinÀÇ ¹ßÇöÀÌ °¨¼ÒÇϰųª µ¹¿¬º¯ÀÌ µî
À¸·Î ±× ±â´ÉÀÌ ¼Ò½ÇµÇ¸é ¼¼Æ÷°£ ºÎÂø·ÂÀÌ °¨¼ÒÇÏ¿© ¾Ï¼¼Æ÷°¡ ¿ø¹ß¾Ï¿¡¼­ ½±°Ô À¯¸®µÇ¾î Àü
ÀÌ°úÁ¤ÀÌ ¹ß»ýÇÑ´Ù. ±×·¯¹Ç·Î membranous E-cadherinÀÇ ¹ßÇö°¨¼Ò´Â ÀÎüÁ¾¾çÀÇ ¾Ç¼ºµµ, Àü
ÀÌ´É·Â ¹× ȯÀÚÀÇ »ýÁ¸À²°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖÀ¸¸ç ½Å¼¼Æ÷¾Ï, Àü¸³¼±¾Ï, µÎ°æºÎ¾Ï, À§¾Ï, ÀÚ±Ã
°æºÎ¾Ï µîÀÇ ¿©·¯ÀÎüÁ¾¾ç¿¡¼­ À¯·ÂÇÑ ¿¹ÈÄÀÎÀÚ°¡ µÉ ¼ö ÀÖÀ½ÀÌ º¸°íµÇ¾ú´Ù.
ÀÌ¿¡ ÀúÀÚµéÀº ¹æ±¤ ÀÌÇ༼Æ÷¾Ï ȯÀÚ 75¿¹¸¦ ´ë»óÀ¸·Î À̵éÀÇ ÆĶóÇÉ Æ÷¸ÅÁ¶Á÷¿¡¼­
membranous E-cadherinÀÇ ¹ßÇöµµ º¯È­¸¦ ºÐÈ­µµ, º´±â ¹× »ýÁ¸·ü°úÀÇ °ü°è¸¦ ºÐ¼®ÇÏ¿© ¹æ
±¤ ÀÌÇà»óÇǾϿ¡¼­ membranous E-cadherinÀÇ ¿¹ÈÄÀû ÀÎÀڷμ­ÀÇ À¯¿ë¼º¿¡ ´ëÇØ Æò°¡ÇÏ°í
ÀÚ ÇÏ¿´´Ù.

Purpose : E-cadherin, a cell adhesive molecule that plays a diverse role in cell-cell and
cell-matrix interaction, is essential for maintaining epithelial intercellular adhesion and
acts particularly as a suppressor of invasive ability of cancer. To determine the potential
prognostic values of membranous E-cadherin, we evaluated the correlation between the
clinical outcome and it¡¯s expression in patients with transitional cell carcinoma of the
bladder.
Materials and Methods : Membranous E-cadherin immunoreactivity was evaluated in 75
cases of transitional bladder cancer and 15 controls (5 cases of cystitis and 10 normal
controls). The expression of membranous E-cadherin were compared with histological
grade, T category of TNM stage, and survival.
Results : Abnormal immunohistochemical expression of membranous E-cadherin was
observed in 53 (70.7%) patients with bladder cancer and undetected in controls.
Abnormal immunohistochemical expression of membranous E-cadherin was significantly
correlated with grade (p<0.01) and T category of TNM stage (p<0.01) of transitional
cell carcinoma of the bladder. Progression to invasive cancer occurred in 6 patients with
45 superficial bladder cancer and 5 of them showed abnormal expression of E-cadherin,
which had statistical significance (p<0.05) but not with recurrence. There was
statistically significant correlation between the abnormal expression of E-cadherin and
poor prognosis(p<0.01).
Conclusions : We conclude that abnormal expression of membranous E-cadherin is a
useful prognostic marker in patients with transitional bladder cancer.

Å°¿öµå

E-cadherin; Bladder cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS